← Metformin × cardiovascular events

SynthesisDiabetes, obesity & metabolism2021

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.

Brendon L Neuen et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 743 people · 2021

Randomised comparison

Probably reduced cardiovascular events

−18%−29% to −14%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.82, 95% CI 0.71–0.86

Randomised comparison

Probably reduced cardiovascular events

−21%−27% to −14%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.79, 95% CI 0.73–0.86

Randomised comparison

Probably reduced cardiovascular events

−26%−37% to −13%

Bigger than 6 in 10 for cardiovascular events

As reported

HR 0.74, 95% CI 0.63–0.87

Range includes no effect

No clear effect on cardiovascular events

−7%−13% to +0%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.93, 95% CI 0.87–1.00

Four numbers in the abstract

the abstract, start to end

… without concomitant metformin use (HR 0.93, 95% CI 0.87-1.00 and HR 0.82, 95% CI 0.71-0.86, …

… irrespective of metformin use (HR 0.79, 95% CI 0.73-0.86 and HR 0.74, 95% CI 0.63-0.87, …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.930.87–1.00
Cardiovascular events
HR 0.820.71–0.86
Cardiovascular events
HR 0.790.73–0.86
Cardiovascular events
HR 0.740.63–0.87
MetforminCardiovascular events
1 / 3

37 papers cite it

2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 33043620